MPJE Mock Exam Questions and Answers with
Explanations (2026/2027)
Multistate Pharmacy Jurisprudence Examination (MPJE) Mock Examination | Core Domains:
Federal Pharmacy Law (Controlled Substances Act, Food, Drug & Cosmetic Act), State-Specific
Pharmacy Practice Act & Regulations, Pharmacy Practice Standards & Ethics, Prescription
Requirements & Processing, Controlled Substance Ordering, Dispensing & Recordkeeping,
Patient Counseling & Privacy (HIPAA), Sterile & Non-Sterile Compounding Regulations, and
Pharmacy Management & Inventory Controls | Pharmacy Licensure Focus | Jurisprudence
Mock Exam Format
Exam Structure
This MPJE Mock Exam simulates the official 120-question, multiple-choice examination for the
2026/2027 testing cycle. Note: The MPJE is state-specific; this mock exam provides a general
federal and model state law framework.
Introduction
This MPJE Mock Exam for the 2026/2027 cycle is designed to assess knowledge of the laws and
regulations governing pharmacy practice. The content integrates federal law with common
state-level regulatory themes, testing the application of legal principles to practice-based
scenarios. It emphasizes the critical thinking required to distinguish between similar legal
concepts and apply them correctly to ensure compliant and ethical pharmacy operations.
Answer Format
All correct answers and legal conclusions must be presented in bold and green, followed by
detailed explanations that cite the relevant federal statute (e.g., CSA, FDCA), refer to model state
pharmacy act provisions, and walk through the legal reasoning step-by-step to justify the correct
application of the law.
1. Federal Law – Controlled Substances Act (CSA): Under the CSA, which schedule
includes drugs with high abuse potential and no accepted medical use in the U.S.?
A) Schedule II
,B) Schedule III
C) Schedule I
D) Schedule V
Explanation: The Controlled Substances Act (21 U.S.C. § 812) defines Schedule I as
substances with high potential for abuse, no currently accepted medical use in treatment in the
U.S., and a lack of accepted safety for use under medical supervision. Examples include heroin,
LSD, and marijuana (federally). Schedules II–V have accepted medical uses.
2. Prescription Requirements: Which of the following is NOT required on a valid
prescription for a Schedule II controlled substance under federal law?
A) Patient’s full name and address
B) Prescriber’s DEA number
C) Refill authorization
D) Date of issue
Explanation: Per 21 CFR § 1306.05, Schedule II prescriptions must include patient
name/address, prescriber name/DEA/address, drug name/strength/directions, quantity, and
date. Refills are prohibited for Schedule II drugs under 21 CFR § 1306.14(a)—thus, refill
authorization is not only unnecessary but illegal.
3. HIPAA Privacy Rule: When may a pharmacist disclose protected health information (PHI)
without patient authorization?
A) To a family member who calls asking for the patient’s medication list
B) For treatment, payment, or healthcare operations (TPO)
C) To a pharmaceutical sales representative
D) For marketing purposes
,Explanation: The HIPAA Privacy Rule (45 CFR § 164.506) permits use/disclosure of PHI
without authorization for Treatment, Payment, and Healthcare Operations (TPO). Disclosures
to family members require patient agreement or professional judgment in limited
circumstances (e.g., incapacitated patient), but not routine release.
4. State Pharmacy Law – Pharmacist-in-Charge (PIC): How often must the
Pharmacist-in-Charge conduct a complete inventory of Schedule II controlled substances in
most states?
A) Monthly
B) Biennially (every 2 years), or upon change of PIC
C) Weekly
D) Only at year-end
Explanation: While federal law (21 CFR § 1304.11) requires an initial inventory and then
every 2 years, most state boards (e.g., Model Pharmacy Act § 10-5) also require an inventory
when a new PIC assumes responsibility. This ensures accountability during transitions.
5. Controlled Substance Ordering: What form must be used to order Schedule II controlled
substances electronically?
A) DEA Form 222
B) CSOS (Controlled Substance Ordering System)
C) FDA Form 356h
D) NABP PMP report
Explanation: As of 2023, DEA Form 222 (paper) is obsolete. All Schedule II orders must be
placed via the DEA’s CSOS electronic system (21 CFR § 1301.74), which requires two-factor
authentication and digital signatures from registered users.
6. Compounding – Non-Sterile: Under USP <795>, what is the beyond-use date (BUD) for
a non-aqueous oral liquid compounded from solid ingredients?
, A) 24 hours
B) 14 days
C) Up to the time remaining on the earliest expiring ingredient, not to exceed 6
months
D) 30 days
Explanation: USP <795> states that for non-aqueous formulations (e.g., suspensions in oil),
the BUD may extend up to the expiration date of the earliest expiring component, but must not
exceed 6 months. This differs from aqueous liquids, which typically have shorter BUDs (e.g., 14
days refrigerated).
7. Ethics – Conflicts of Interest: A pharmacist receives a bonus from a manufacturer for
switching patients to a specific brand-name drug. This likely violates:
A) FDA labeling rules
B) State pharmacy board rules on kickbacks and fiduciary duty
C) OSHA regulations
D) Medicare Part D formulary guidelines
Explanation: Most state pharmacy acts (e.g., Model Act § 5-2) prohibit pharmacists from
accepting incentives that compromise professional judgment. This also potentially violates the
federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) if federal healthcare programs are
involved.
8. Prescription Processing – Validity: A prescription for oxycodone 30 mg #30 with “Refill
5 times” is presented. What should the pharmacist do?
A) Fill all 6 fills (initial + 5 refills)
Explanations (2026/2027)
Multistate Pharmacy Jurisprudence Examination (MPJE) Mock Examination | Core Domains:
Federal Pharmacy Law (Controlled Substances Act, Food, Drug & Cosmetic Act), State-Specific
Pharmacy Practice Act & Regulations, Pharmacy Practice Standards & Ethics, Prescription
Requirements & Processing, Controlled Substance Ordering, Dispensing & Recordkeeping,
Patient Counseling & Privacy (HIPAA), Sterile & Non-Sterile Compounding Regulations, and
Pharmacy Management & Inventory Controls | Pharmacy Licensure Focus | Jurisprudence
Mock Exam Format
Exam Structure
This MPJE Mock Exam simulates the official 120-question, multiple-choice examination for the
2026/2027 testing cycle. Note: The MPJE is state-specific; this mock exam provides a general
federal and model state law framework.
Introduction
This MPJE Mock Exam for the 2026/2027 cycle is designed to assess knowledge of the laws and
regulations governing pharmacy practice. The content integrates federal law with common
state-level regulatory themes, testing the application of legal principles to practice-based
scenarios. It emphasizes the critical thinking required to distinguish between similar legal
concepts and apply them correctly to ensure compliant and ethical pharmacy operations.
Answer Format
All correct answers and legal conclusions must be presented in bold and green, followed by
detailed explanations that cite the relevant federal statute (e.g., CSA, FDCA), refer to model state
pharmacy act provisions, and walk through the legal reasoning step-by-step to justify the correct
application of the law.
1. Federal Law – Controlled Substances Act (CSA): Under the CSA, which schedule
includes drugs with high abuse potential and no accepted medical use in the U.S.?
A) Schedule II
,B) Schedule III
C) Schedule I
D) Schedule V
Explanation: The Controlled Substances Act (21 U.S.C. § 812) defines Schedule I as
substances with high potential for abuse, no currently accepted medical use in treatment in the
U.S., and a lack of accepted safety for use under medical supervision. Examples include heroin,
LSD, and marijuana (federally). Schedules II–V have accepted medical uses.
2. Prescription Requirements: Which of the following is NOT required on a valid
prescription for a Schedule II controlled substance under federal law?
A) Patient’s full name and address
B) Prescriber’s DEA number
C) Refill authorization
D) Date of issue
Explanation: Per 21 CFR § 1306.05, Schedule II prescriptions must include patient
name/address, prescriber name/DEA/address, drug name/strength/directions, quantity, and
date. Refills are prohibited for Schedule II drugs under 21 CFR § 1306.14(a)—thus, refill
authorization is not only unnecessary but illegal.
3. HIPAA Privacy Rule: When may a pharmacist disclose protected health information (PHI)
without patient authorization?
A) To a family member who calls asking for the patient’s medication list
B) For treatment, payment, or healthcare operations (TPO)
C) To a pharmaceutical sales representative
D) For marketing purposes
,Explanation: The HIPAA Privacy Rule (45 CFR § 164.506) permits use/disclosure of PHI
without authorization for Treatment, Payment, and Healthcare Operations (TPO). Disclosures
to family members require patient agreement or professional judgment in limited
circumstances (e.g., incapacitated patient), but not routine release.
4. State Pharmacy Law – Pharmacist-in-Charge (PIC): How often must the
Pharmacist-in-Charge conduct a complete inventory of Schedule II controlled substances in
most states?
A) Monthly
B) Biennially (every 2 years), or upon change of PIC
C) Weekly
D) Only at year-end
Explanation: While federal law (21 CFR § 1304.11) requires an initial inventory and then
every 2 years, most state boards (e.g., Model Pharmacy Act § 10-5) also require an inventory
when a new PIC assumes responsibility. This ensures accountability during transitions.
5. Controlled Substance Ordering: What form must be used to order Schedule II controlled
substances electronically?
A) DEA Form 222
B) CSOS (Controlled Substance Ordering System)
C) FDA Form 356h
D) NABP PMP report
Explanation: As of 2023, DEA Form 222 (paper) is obsolete. All Schedule II orders must be
placed via the DEA’s CSOS electronic system (21 CFR § 1301.74), which requires two-factor
authentication and digital signatures from registered users.
6. Compounding – Non-Sterile: Under USP <795>, what is the beyond-use date (BUD) for
a non-aqueous oral liquid compounded from solid ingredients?
, A) 24 hours
B) 14 days
C) Up to the time remaining on the earliest expiring ingredient, not to exceed 6
months
D) 30 days
Explanation: USP <795> states that for non-aqueous formulations (e.g., suspensions in oil),
the BUD may extend up to the expiration date of the earliest expiring component, but must not
exceed 6 months. This differs from aqueous liquids, which typically have shorter BUDs (e.g., 14
days refrigerated).
7. Ethics – Conflicts of Interest: A pharmacist receives a bonus from a manufacturer for
switching patients to a specific brand-name drug. This likely violates:
A) FDA labeling rules
B) State pharmacy board rules on kickbacks and fiduciary duty
C) OSHA regulations
D) Medicare Part D formulary guidelines
Explanation: Most state pharmacy acts (e.g., Model Act § 5-2) prohibit pharmacists from
accepting incentives that compromise professional judgment. This also potentially violates the
federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) if federal healthcare programs are
involved.
8. Prescription Processing – Validity: A prescription for oxycodone 30 mg #30 with “Refill
5 times” is presented. What should the pharmacist do?
A) Fill all 6 fills (initial + 5 refills)
